Selpercatinib is a RET kinase inhibitor extracted from patent WO2018071447A1, Compound Example 163, has an IC50 of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M) , and RET (G810R), respectively
*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p>Selpercatinib (LOXO-292) is a highly selective RET inhibitor used in oncology. Its <strong>molecular formula</strong> is C<sub>24</sub>H<sub>26</sub>F<sub>3</sub>N<sub>7</sub>O<sub>3</sub>, with CAS No. 1854029-65-4.</p>
<h3>Application</h3>
<ul>
<li><strong>Oncology:</strong> Treatment of RET fusion-positive non-small cell lung cancer.</li>
<li><strong>Rare Diseases:</strong> Management of RET-mutant medullary thyroid carcinoma.</li>
<li><strong>Pharmaceutical R&D:</strong> Active pharmaceutical ingredient for targeted therapy development.</li>
</ul>
<h3>Precautions</h3>
<p>Requires strict clinical monitoring for hepatotoxicity and QT prolongation. Store under controlled conditions at 2°C to 8°C to maintain stability.</p>